Results 161 to 170 of about 106,501 (287)

Differential regulation of SIRT5 activity by reduced nicotinic acid riboside (NARH). [PDF]

RSC Chem Biol
Hamza A, Donu D, Boyle E, Madhusudhana R, Curry A, Cen Y.   +5 more
europepmc   +1 more source

Synthesis, Biological Activity and Molecular Docking Studies of Novel Nicotinic Acid Derivatives. [PDF]

Int J Mol Sci, 2022
Paruch K, Biernasiuk A, Khylyuk D, Paduch R, Wujec M, Popiołek Ł.   +5 more
europepmc   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Structural, electronic, intermolecular interaction, reactivity, vibrational spectroscopy, charge transfer, Hirshfeld surface analysis, pharmacological and hydropathy plot on 5-Bromo nicotinic acid - Antiviral study (Hepatitis A, B, and C). [PDF]

Heliyon, 2023
R S, Mahalakshmi S, Kumaran S, Kadaikunnan S, Abbas G, Muthu S.   +5 more
europepmc   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

The nicotinamide hypothesis revisited-plant defense signaling integrating PARP, nicotinamide, nicotinic acid, epigenetics, and glutathione. [PDF]

FEBS Lett
Berglund T, Ohlsson AB.
europepmc   +1 more source

Expanding the Myxochelin Natural Product Family by Nicotinic Acid Containing Congeners. [PDF]

Molecules, 2021
Frank NA, Széles M, Akone SH, Rasheed S, Hüttel S, Frewert S, Hamed MM, Herrmann J, Schuler SMM, Hirsch AKH, Müller R.   +10 more
europepmc   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

Nicotinic acid protects against hepatic ischemia-reperfusion injury via suppressing mitochondrial damage-induced ferroptosis. [PDF]

Liver Res
Zeng Q, Sun Y, Lei M, Liu Z, Yan X, Li R, Zheng J, Zha J, Zhang L, Guan X, Yao J.   +10 more
europepmc   +1 more source

Nicotinic acid mononucleotide is an allosteric SARM1 inhibitor promoting axonal protection. [PDF]

Exp Neurol, 2021
Sasaki Y, Zhu J, Shi Y, Gu W, Kobe B, Ve T, DiAntonio A, Milbrandt J.   +7 more
europepmc   +1 more source